Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Todd A Triplett

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Medrxiv : the Preprint Server for Health Sciences|December 18, 2023
SARS-CoV-2 Humoral Immune Responses in Convalescent Individuals Over 12 Months Reveal Severity-Dependent Antibody DynamicsNadia Siles, Maisey Schuler, Cole Maguire, et al.
Cancers|January 11, 2024
First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid TumorsAnna R Schreiber, Jodi A Kagihara, Bradley R Corr, et al.
Communications Medicine|May 2, 2025
SARS-CoV-2 humoral immune responses in convalescent individuals over 12 months reveal severity-dependent antibody dynamicsNadia Siles Alvarado, Maisey Schuler, Cole Maguire, et al.
Nature Biotechnology|July 17, 2018
Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzymeTodd A Triplett, Kendra C Garrison, Nicholas Marshall, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Medrxiv : the Preprint Server for Health Sciences|December 18, 2023
SARS-CoV-2 Humoral Immune Responses in Convalescent Individuals Over 12 Months Reveal Severity-Dependent Antibody DynamicsNadia Siles, Maisey Schuler, Cole Maguire, et al.
Cancers|January 11, 2024
First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid TumorsAnna R Schreiber, Jodi A Kagihara, Bradley R Corr, et al.
Communications Medicine|May 2, 2025
SARS-CoV-2 humoral immune responses in convalescent individuals over 12 months reveal severity-dependent antibody dynamicsNadia Siles Alvarado, Maisey Schuler, Cole Maguire, et al.
Nature Biotechnology|July 17, 2018
Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzymeTodd A Triplett, Kendra C Garrison, Nicholas Marshall, et al.
Pageof 2